Cariprazine and Tovorafenib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cariprazine
Tovorafenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Cariprazine (Vraylar) is broken down in your body by an enzyme called CYP3A4. Tovorafenib (Ojemda) can speed that enzyme up. The tricky part is that this same enzyme both creates and clears cariprazine's active forms, so nobody knows for sure whether the medicine ends up working stronger or weaker when the two are taken together.
Because that net effect is uncertain, this combination is generally not recommended. Please don't stop or change either medicine on your own. Instead, let your doctor or pharmacist know you take both. Your care team can decide the safest plan and keep a closer eye on how you're doing.
Mechanism: Tovorafenib may induce CYP3A4, the enzyme responsible for both formation and elimination of cariprazine's active metabolites (desmethyl- and didesmethyl-cariprazine). Because CYP3A4 governs both activation and clearance, the net effect on total active exposure has not been characterized.
- Direction: Unclear (could reduce or alter active metabolite exposure).
- Evidence: Theoretical; not formally studied.
- Onset: Unspecified; enzyme induction typically develops over days to weeks.
- Severity: Major; coadministration not recommended.
Management: Avoid the combination where possible. If used together, individualize dosing and monitor closely for altered efficacy or adverse effects.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
It is advised against giving cariprazine (which acts as a CYP3A4 substrate) together with a CYP3A4 inducer. The enzyme CYP3A4 governs both the generation and clearance of cariprazine's active metabolites. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall net effect remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
This combination is generally not recommended because we cannot predict whether tovorafenib will make cariprazine work more strongly or less effectively.
- Keep taking both medicines as prescribed unless your care team tells you otherwise.
- Tell your prescriber and pharmacist that you take both so they can decide whether an alternative is a better fit.
- If the two are used together, your dose may need to be adjusted and individualized, and your team may monitor you more closely for changes in symptoms or side effects.
- Report new or worsening symptoms, or a return of the symptoms cariprazine treats.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Cariprazine and Tovorafenib together?
Combining cariprazine with tovorafenib is not recommended because tovorafenib may alter cariprazine's active metabolite levels in an unpredictable way; talk with your doctor or pharmacist before taking both. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Tovorafenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Tovorafenib interaction managed?
This combination is generally not recommended because we cannot predict whether tovorafenib will make cariprazine work more strongly or less effectively. Keep taking both medicines as prescribed unless your care team tells you otherwise. Tell your prescriber and pharmacist that you take both so they can decide whether an alternative is a better fit. If the two are used together, your dose may need… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Cariprazine or Tovorafenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Cariprazine
Keep reading about Tovorafenib
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist